Ladder Capital Free cash flow decreased by 122.4% to -$8.73M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 70.5%, from -$29.60M to -$8.73M. Over 2 years (FY 2021 to FY 2025), Free cash flow shows relatively stable performance with a 2.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $33.49M | $34.36M | $51.87M | -$30.79M | $40.88M | $36.47M | $53.20M | $110.78M | $76.97M | $56.67M | -$21.75M | $44.95M | $166.00M | -$29.60M | $43.41M | $25.86M | $39.01M | -$8.73M |
| QoQ Change | — | +2.6% | +51.0% | -159.3% | +232.8% | -10.8% | +45.9% | +108.2% | -30.5% | -26.4% | -138.4% | +306.7% | +269.3% | -117.8% | +246.7% | -40.4% | +50.8% | -122.4% |
| YoY Change | — | — | — | — | +22.0% | +6.1% | +2.6% | +459.9% | +111.1% | +6.5% | -119.6% | — | +115.7% | -36.1% | -3.4% | -84.4% | — | +70.5% |